Payment overview · 2025
General Payments
$545.00
27 reported records · 11 companies
Healthcare provider profile · identity verified
Rose Romulus
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · AUSTELL, GA · NPI 1770909236
Verified facts
What the public records show
CMS Open Payments records show Rose Romulus received $545.00 in general payments during 2025 across 27 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna, Jardiance.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Invega Sustenna by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $231.80 | 42.5% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $111.24 | 20.4% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.85 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.51 | 6.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.52 | 5.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.62 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.59 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.30 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.66 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.12 | 2.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.79 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $545.00 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $119.76 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $112.04 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $111.24 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $95.16 | 5 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 182 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
182 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 87 |
| Trazodone Hcl | Trazodone Hcl | 291 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 40 |
| Metformin Hcl | Metformin Hcl | 262 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 261 | 38 |
| Benztropine Mesylate | Benztropine Mesylate | 243 | 28 |
| Carvedilol | Carvedilol | 233 | 40 |
| Divalproex Sodium | Divalproex Sodium | 215 | 31 |
| Losartan Potassium | Losartan Potassium | 211 | 50 |
| Invega Sustenna | Paliperidone Palmitate | 182 | 18 |
| Omeprazole | Omeprazole | 182 | 39 |
| Sertraline Hcl | Sertraline Hcl | 168 | 24 |
| Lisinopril | Lisinopril | 164 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 31 |
| Risperidone | Risperidone | 143 | 18 |
| Olanzapine | Olanzapine | 136 | 20 |
| Gemfibrozil | Gemfibrozil | 131 | 31 |
| Gabapentin | Gabapentin | 130 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 21 |
| Donepezil Hcl | Donepezil Hcl | 92 | 20 |
| Lithium Carbonate | Lithium Carbonate | 76 | suppressed |
| Famotidine | Famotidine | 74 | 13 |
| Haloperidol | Haloperidol | 72 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | suppressed |
| Aripiprazole | Aripiprazole | 63 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 25 |
| Alprazolam | Alprazolam | 59 | 11 |
| Buspirone Hcl | Buspirone Hcl | 59 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Clonazepam | Clonazepam | 59 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 14 |
| Glipizide | Glipizide | 58 | 18 |
| Nifedipine Er | Nifedipine | 58 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Meloxicam | Meloxicam | 52 | 23 |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Topiramate | Topiramate | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 16 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | 11 |
| Paliperidone Er | Paliperidone | 41 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 39 | suppressed |
| Furosemide | Furosemide | 39 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 17 |
| Glipizide Er | Glipizide | 34 | 11 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 27 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 15 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Olanzapine Odt | Olanzapine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 19 | suppressed |
| Prednisone | Prednisone | 19 | 15 |
| Temazepam | Temazepam | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 12 |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $545.00 · 27 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ACCRUFER, AIRSUPRA, CAPLYTA, COBENFY, Cologuard Collection Kit, INVEGA SUSTENNA, INVEGA TRINZA, JARDIANCE, MOUNJARO, OTEZLA, REPATHA, REXULTI, UZEDY, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error